Featured Research

from universities, journals, and other organizations

First successful clinical trial to protect the brain from damage caused by stroke

Date:
October 8, 2012
Source:
University Health Network (UHN)
Summary:
Scientists and clinicians have demonstrated that a neuroprotectant drug protects the human brain against the damaging effects of stroke. In patients who had ruptured brain aneurysm, which comprise a population of patients at very high risk of neurological damage, those treated with Tat-NR2B9c all had good neurological outcomes, whereas only 68% of those treated with placebo had good outcomes.

A team of Canadian scientists and clinicians, led by Dr. Michael Hill of the Calgary Stroke Program at Foothills Medical Centre and University of Calgary's Hotchkiss Brain Institute (HBI), have demonstrated that a neuroprotectant drug, developed by Dr. Michael Tymianski at the Krembil Neuroscience Centre, located at the Toronto Western Hospital, protects the human brain against the damaging effects of stroke.
Credit: © forestpath / Fotolia

A team of Canadian scientists and clinicians, led by Dr. Michael Hill of the Calgary Stroke Program at Foothills Medical Centre and University of Calgary's Hotchkiss Brain Institute (HBI), have demonstrated that a neuroprotectant drug, developed by Dr. Michael Tymianski at the Krembil Neuroscience Centre, located at the Toronto Western Hospital, protects the human brain against the damaging effects of stroke.

The study, "Safety and efficacy of NA-1 for neuroprotection in iatrogenic stroke after endovascular aneurysm repair: a randomized controlled trial," published online October 8 in The Lancet Neurology, was conducted concurrently with a laboratory study published in Science Translational Medicine, that predicted the benefits of the stroke drug.

This landmark clinical trial was a randomized, double blinded, multi-centre trial that was conducted in Canada and the USA. The study evaluated the effectiveness of NA-1[Tat-NR2B9c] when it was administered after the onset of small strokes that are incurred by patients who undergo neurointerventional procedures to repair brain aneurysms. This type of small ischemic stroke occurs in over 90% of aneurysm patients after such a procedure, but usually does not cause overt neurological disability.

In the clinical trial, patients were randomized to receive either Tat-NR2B9c or placebo. Those treated with Tat-NR2B9c showed a reduction in the amount of brain damage sustained as a result of the aneurysm repair procedure. Also, in patients who had ruptured brain aneurysm, which comprise a population of patients at very high risk of neurological damage, those treated with Tat-NR2B9c all had good neurological outcomes, whereas only 68% of those treated with placebo had good outcomes.

"The results of this clinical trial represent a major leap forward for stroke research," said Dr. Hill. "There have been over 1,000 attempts to develop such drugs, which have failed to make the leap between success in the lab and in humans."

"This clinical trial is, to our knowledge, the first time that a drug aimed at increasing the resistance of the brain to stroke, has been shown to reduce stroke damage in humans. No efforts should be spared to develop it further," said Dr. Michael Tymianski, who oversaw the development of Tat-NR2B9c from its invention in his lab, through to clinical trials.

Currently, t-PA is the only widely approved acute stroke therapy. It works by unblocking the arteries to the brain, however, this treatment is only beneficial for a portion of stroke victims. It also has serious potential for side-effects, including bleeding in the brain.

"Through our lab research and clinical trial, we now have a better method of predicting whether a stroke drug may be effective in humans and we now have the evidence that there is a neuroprotectant that can prevent damage in the brain caused by reduced blood flow," said Dr. Tymianski, inventor of NA-1 and one of the study's authors. "The benefits of this can be explored not only for stroke, but for other conditions such as vascular dementia."


Story Source:

The above story is based on materials provided by University Health Network (UHN). Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael D Hill, Renee H Martin, David Mikulis, John H Wong, Frank L Silver, Karel G terBrugge, Geneviθve Milot, Wayne M Clark, R Loch MacDonald, Michael E Kelly, Melford Boulton, Ian Fleetwood, Cameron McDougall, Thorsteinn Gunnarsson, Michael Chow, Cheemun Lum, Robert Dodd, Julien Poublanc, Timo Krings, Andrew M Demchuk, Mayank Goyal, Roberta Anderson, Julie Bishop, David Garman, Michael Tymianski. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 2012; DOI: 10.1016/S1474-4422(12)70225-9

Cite This Page:

University Health Network (UHN). "First successful clinical trial to protect the brain from damage caused by stroke." ScienceDaily. ScienceDaily, 8 October 2012. <www.sciencedaily.com/releases/2012/10/121008091454.htm>.
University Health Network (UHN). (2012, October 8). First successful clinical trial to protect the brain from damage caused by stroke. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/10/121008091454.htm
University Health Network (UHN). "First successful clinical trial to protect the brain from damage caused by stroke." ScienceDaily. www.sciencedaily.com/releases/2012/10/121008091454.htm (accessed July 30, 2014).

Share This




More Mind & Brain News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

It's Not Just Facebook: OKCupid Experiments With Users Too

It's Not Just Facebook: OKCupid Experiments With Users Too

Newsy (July 29, 2014) — If you've been looking for love online, there's a chance somebody has been looking at how you're looking. Video provided by Newsy
Powered by NewsLook.com
How Your Face Can Leave A Good Or Bad First Impression

How Your Face Can Leave A Good Or Bad First Impression

Newsy (July 29, 2014) — Researchers have found certain facial features can make us seem more attractive or trustworthy. Video provided by Newsy
Powered by NewsLook.com
Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) — A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com
University Quiz Implies Atheists Are Smarter Than Christians

University Quiz Implies Atheists Are Smarter Than Christians

Newsy (July 25, 2014) — An online quiz from a required course at Ohio State is making waves for suggesting atheists are inherently smarter than Christians. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins